Carrier free indomethacin microparticles for dry powder inhalation
In conclusion, a promising powder formulation for DPIs has been developed to treat, locally and systemically, inflammatory diseases.Graphical abstract
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
More News: Arthritis | Asthma | Drugs & Pharmacology | Indomethacin | Lactose | Osteoarthritis | Pain | Rheumatoid Arthritis | Rheumatology | Study